ArticleGastro hep advances2026
Serological Remission Defined by Anti-Integrin αvβ6 Antibody Predicts Long-Term Clinical Remission of Ulcerative Colitis.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Although management of ulcerative colitis (UC) has advanced with the treat-to-target strategy, biomarkers for relapse remain limited. The anti-integrin αvβ6 (V6) antibody reflects epithelial injury and could be a serological biomarker in UC. This retrospective cohort study evaluated whether the V6 antibody can predict relapse and be a serological target for sustained clinical remission. Methods: We measured V6 antibody levels in serum samples from patients with UC in clinical remission who had ≥3 years of follow-up. Relapse was defined as the need for initiation or modification (dose adjustment or switching) of systemic corticosteroids or molecular targeted drugs, or surgical intervention, due to worsening of disease activity (Lichtiger index ≥4). The ability of the V6 antibody to predict relapse and the cutoff value were investigated. Longitudinal intraindividual stability of the antibody level was evaluated. Results: Fifty-three of 149 patients experienced relapse. Seven and 2 patients required hospitalization and colectomy, respectively. The 1-year, 2-year, and 3-year cumulative relapse rates were 12.1%, 22.2%, and 32.9%, respectively. V6 antibody levels were significantly higher in patients who relapsed. Receiver-operating characteristic curve analyses showed considerable predictive ability (area under the curve, 0.73) at 1 to 3 years. The optimal cutoff for predicting 1-year relapse was 11.99U/mL, while ≤4.23U/mL yielded the highest 3-year negative predictive value. Cumulative 1-year, 2-year, and 3-year relapse rates were 0.0%, 0.0%, and 8.8%, respectively, in patients with ≤4.23U/mL. V6 antibody levels remained stable intraindividually and decreased on molecular-targeted therapy. Conclusion: The V6 antibody predicted long-term clinical remission of UC. The definition of serological response (≤11.99U/mL) and remission (≤4.23U/mL) based on this antibody potentially serves as a noninvasive therapeutic target in UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.